Vectus Biosystems Ltd (AU:VBS) — Market Cap & Net Worth
Market Cap & Net Worth: Vectus Biosystems Ltd (VBS)
Vectus Biosystems Ltd (AU:VBS) has a market capitalization of $5.67 Million (AU$8.01 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28321 globally and #1502 in its home market, demonstrating a 11.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vectus Biosystems Ltd's stock price AU$0.15 by its total outstanding shares 53433331 (53.43 Million). Review Vectus Biosystems Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
Vectus Biosystems Ltd Market Cap History: 2016 to 2026
Vectus Biosystems Ltd's market capitalization history from 2016 to 2026. Data shows change from $59.74 Million to $5.67 Million (-20.24% CAGR).
Vectus Biosystems Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vectus Biosystems Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.23x
Vectus Biosystems Ltd's market cap is 14.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $59.74 Million | $75.07K | -$3.21 Million | 795.78x | N/A |
| 2017 | $51.04 Million | $49.34K | -$3.79 Million | 1034.52x | N/A |
| 2018 | $22.31 Million | $1.83K | -$2.59 Million | 12209.31x | N/A |
| 2019 | $22.31 Million | $220.00 | -$1.60 Million | 101392.80x | N/A |
| 2020 | $45.37 Million | $51.19K | -$3.00 Million | 886.36x | N/A |
| 2021 | $53.31 Million | $180.00 | -$3.86 Million | 296158.64x | N/A |
| 2022 | $27.60 Million | $1.30 Million | -$3.99 Million | 21.23x | N/A |
| 2023 | $11.34 Million | $1.35 Million | -$3.45 Million | 8.37x | N/A |
| 2024 | $2.91 Million | $1.14 Million | -$2.34 Million | 2.56x | N/A |
| 2025 | $6.81 Million | $478.18K | -$1.78 Million | 14.23x | N/A |
Competitor Companies of VBS by Market Capitalization
Companies near Vectus Biosystems Ltd in the global market cap rankings as of June 21, 2026.
Key companies related to Vectus Biosystems Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Vectus Biosystems Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Vectus Biosystems Ltd's market cap moved from $59.74 Million to $ 5.67 Million, with a yearly change of -20.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$5.67 Million | -16.67% |
| 2025 | AU$6.81 Million | +133.77% |
| 2024 | AU$2.91 Million | -74.33% |
| 2023 | AU$11.34 Million | -58.90% |
| 2022 | AU$27.60 Million | -48.23% |
| 2021 | AU$53.31 Million | +17.50% |
| 2020 | AU$45.37 Million | +103.39% |
| 2019 | AU$22.31 Million | 0.00% |
| 2018 | AU$22.31 Million | -56.30% |
| 2017 | AU$51.04 Million | -14.56% |
| 2016 | AU$59.74 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Vectus Biosystems Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.67 Million USD |
| MoneyControl | $5.67 Million USD |
| MarketWatch | $5.67 Million USD |
| marketcap.company | $5.67 Million USD |
| Reuters | $5.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more